Wilms’ Tumor News and Research

RSS

Lin28 gene may hold clues to regeneration of damaged kidneys in adults

Nearly one-third of cases of Wilms tumor, a pediatric cancer of the kidney, are linked to a gene called Lin28, according to research from Boston Children's Hospital. Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the gene hold therapeutic promise for children with Wilms.

15 Apr 2014

Study reveals epigenetic mechanisms contribute to chronic disease susceptibility prior to birth

If you think stress is killing you, you may be right, but what you don't know is that stress might have harmed your health even before you were born. In a new report appearing in the August 2013 issue of The FASEB Journal, Harvard researchers find that epigenetic disruptions, which are associated with chronic disease later in life, are already common at birth.

2 Aug 2013

MD Anderson researchers named Fellows to new AACR academy

Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.

29 Mar 2013

Routine use of pelvic CT scans in Wilms tumor questioned

Omitting pelvic computed tomography scans from the routine surveillance of off-therapy patients with Wilms tumor could reduce radiation exposure without compromising relapse detection rates, researchers report.

2 Jul 2012

Survivors of childhood cancers are at increased risk for GI cancers

Survivors of childhood cancers are at an increased risk of another battle with cancer later in life, according to new research published online June 4 by the Annals of Internal Medicine. In the largest study to date of risk for gastrointestinal (GI) cancers among people first diagnosed with cancer before the age of 21, researchers found that childhood cancer survivors develop these malignancies at a rate nearly five times that of the general population.

5 Jun 2012

Folic acid fortification may reduce incidence of some childhood cancers

Researchers from the University of Minnesota and Washington University in St. Louis have found folic acid fortification of grain products in the United States may have an impact on lowering some childhood cancers.

23 May 2012

Folic acid fortification may reduce incidence of Wilms' tumor, PNET in children

Folic acid fortification of foods may reduce the incidence of the most common type of kidney cancer and a type of brain tumors in children, finds a new study by Kimberly J. Johnson, PhD, assistant professor at the Brown School at Washington University in St. Louis, and Amy Linabery, PhD, postdoctoral fellow at the University of Minnesota.

21 May 2012

Researchers discover function and expression of CD97 in malignant gliomas

Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center and Old Dominion University have discovered that suppression of Wilms tumor 1 protein (WT1) results in downregulation of CD97 gene expression in three glioblastoma cell lines and reduces the characteristic invasiveness exhibited by glial tumor cells.

8 Feb 2012

Study examines long-term GI complications in childhood cancer survivors

Individuals who are treated for cancer during childhood have a significantly higher risk of developing gastrointestinal complications - from mild to severe - later in life, according to a study led by the University of California, San Francisco. The findings underscore the need for childhood cancer survivors and their physicians to be aware of these risk factors to ensure patients' ongoing health care needs are met.

21 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Childhood cancer survivors may face high risk of late GI complications after therapy

Patients who received therapy for cancer during childhood have an increased risk of developing gastrointestinal complications later in life, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

5 May 2011

Pediatric urology research papers published in two Elsevier journals

The first World Congress of Pediatric Urology was held in San Francisco in May 2010, bringing together the largest and most successful international congregation of pediatric urologists ever assembled. As part of a collaborative effort, The Journal of Urology and the Journal of Pediatric Urology have together published the landmark papers presented at this meeting.

2 May 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Complete Genomics Inc., a life sciences company focused on human genome sequencing, today announced a collaboration to identify and validate somatic mutations from 50 pediatric cancer cases from multiple research centers across the United States.

7 Sep 2010

Bedford Laboratories launches Dactinomycin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.

12 Jul 2010

Detailed analysis of epigenetics of Wilms tumor reveals similarities to stem cells

A detailed analysis of the epigenetics - factors controlling when and in what tissues genes are expressed - of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys. These findings by Massachusetts General Hospital Cancer Center researchers have revealed new cellular pathways that are critical for Wilms tumor development and may also apply to other pediatric cancers.

4 Jun 2010

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

30 Apr 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

NCI-funded SPORE grant aims to improve kidney cancer treatment

The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.

16 Sep 2009

Childhood cancer risk rises with mother's age

Research from the Masonic Cancer Center, University of Minnesota indicates that a baby born to an older mother may have a slightly increased risk for many of the cancers that occur during childhood.

14 Jul 2009